{"id":"NCT01806597","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-19","primaryCompletion":"2016-11-02","completion":"2016-11-02","firstPosted":"2013-03-07","resultsPosted":"2018-02-22","lastUpdate":"2018-02-22"},"enrollment":205,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Palmoplantar Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"secukinumab 150 mg","otherNames":["AIN457 150 mg"]},{"type":"BIOLOGICAL","name":"secukinumab 300 mg","otherNames":["AIN457 300 mg"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"secukinumab 150mg","type":"EXPERIMENTAL"},{"label":"secukinumab 300 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.","primaryOutcome":{"measure":"Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment","timeFrame":"Week 16","effectByArm":[{"arm":"AIN457 150mg","deltaMin":22,"sd":null},{"arm":"AIN457 300 mg","deltaMin":33.3,"sd":null},{"arm":"Placebo","deltaMin":1.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0002"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":54,"countries":["United States","Australia","Belgium","Canada","Finland","Hungary","Israel","Netherlands","Norway","Portugal","Russia","Slovakia","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":99},"commonTop":["Upper respiratory tract infection","Psoriasis","Nasopharyngitis","Headache","Influenza"]}}